What is Alvotech?
Founded in 2013, Alvotech operates at the intersection of biotechnology and pharmaceutical manufacturing, specializing in the development of biosimilar products. The company's core value proposition lies in its ability to provide cost-effective alternatives to complex biological drugs, thereby increasing patient access to essential treatments for chronic conditions such as Crohn's disease, rheumatoid arthritis, and various cancers. Its robust pipeline, which includes candidates like AVT02, AVT04, and AVT06, positions the firm as a key player in the global biosimilars market. By maintaining a focus on high-quality manufacturing and rigorous clinical development, Alvotech effectively bridges the gap between innovative research and affordable healthcare delivery.
How much funding has Alvotech raised?
Alvotech has raised a total of $928.2M across 9 funding rounds:
Other Financing Round
$300M
Share Placement
$35M
Multiple Rounds
$136M
Debt
$100M
Multiple Rounds
$357.2M
Other Financing Round (2019): $300M with participation from Fuji Pharma
Share Placement (2021): $35M led by ATHOS, Shinhan Financial Group, and Baxter Healthcare
Debt (2022): $50M supported by Alvogen
Debt (2022): $16M featuring Landsbankinn HF
Debt (2022): $70M backed by Morgan Stanley, Oaktree, Farallon Capital Management, and Sculptor Capital
Debt (2023): $100M with participation from At&p Holding
Debt (2026): $117.2M led by GoldenTree Asset Management
Stock/Share Issuance (2026): $165M, investors not publicly disclosed
Debt (2026): $75M featuring GoldenTree Asset Management
Key Investors in Alvotech
Fuji Pharma
A pharmaceutical company focused on the development, manufacturing, and marketing of new drugs, generic drugs, and biosimilars, with a strong presence in the Japanese market.
GoldenTree Asset Management
An employee-owned, global asset management firm specializing in credit-focused opportunities, including high-yield bonds, private credit, and distressed debt.
Alvogen
A pharmaceutical company headquartered in New Jersey that develops, manufactures, and markets generic and parallel-imported drugs on a global scale.
What's next for Alvotech?
Looking ahead, Alvotech is poised to transition from a development-heavy entity to a commercial-scale powerhouse. The recent capital injection will likely be directed toward accelerating the regulatory approval processes for its late-stage pipeline and scaling manufacturing capacity to meet anticipated global demand. As the company continues to navigate the competitive landscape of the pharmaceutical industry, its ability to maintain a disciplined debt-to-equity ratio while simultaneously executing on its clinical milestones will be critical. Investors will be closely monitoring the commercial launch of its lead programs, as these represent the primary catalysts for long-term revenue growth and market share acquisition in the highly regulated biologics sector.
See full Alvotech company page
